FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
What happened
FDA reviewed the website joinsprouthealth.com in August 2025 and found it offers compounded semaglutide and tirzepatide drug products. The site states that "GLP-1 medications are FDA-approved and backed by extensive clinical research," but compounded drugs are not FDA-approved. FDA says the statement is false or misleading and therefore misbrands the products.
What FDA found
The website says its GLP-1 drugs are FDA-approved, which is false for compounded drugs, so the labeling is misleading.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising or promoting a compounded drug with false or misleading claims misbrands that drug.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Selling these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to stop using the misleading FDA-approval language immediately and to send a written response within 15 working days describing the corrective steps taken and how it will prevent repeat violations, with supporting documents.
Who should pay attention
- telehealth platforms selling compounded GLP-1 drugs
- compounding pharmacies that supply online prescribers
- marketing and compliance teams that write drug product website copy
This is a summary. Read the original letter on fda.gov.